Compstatin, specifically the variant ICVVQDWGHHRCT, is primarily used in biomedical research and therapeutic development due to its ability to inhibit the complement system, a part of the immune response. It is particularly effective in targeting the C3 protein, which plays a central role in the complement cascade. This makes it a valuable tool in studying and treating diseases where excessive or uncontrolled complement activation is involved, such as age-related macular degeneration, autoimmune disorders, and inflammatory conditions. Its application extends to the development of novel therapies aimed at modulating immune responses to prevent tissue damage or treat chronic diseases. Additionally, it is used in experimental models to understand the mechanisms of complement-related pathologies and to test potential therapeutic interventions.